Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
On January 21, 2022, AbbVie announced the FDA approval of Skyrizi (risankizumab-rzaa), for the treatment of active psoriatic arthritis in adults.
Download PDF
Return to publications
